Besides, recent studies have highlighted the interesting role of PPARγ agonists as modulators of inflammatory and immunomodulatory drugs through the targeting of the cytokine storm in COVID‐19 patients (Vallée et al., 2019; Vallée & Lecarpentier, 2016, 2018). This evidence concerns the gene PPARG and COVID-19.